10-Q: Bullfrog AI Holdings Reports Third Quarter 2024 Results, Cites Ongoing Investment in AI Platform and Drug Development

Bullfrog AI Holdings reported its third quarter 2024 results, highlighting continued investment in its AI platform and drug development programs despite no revenue for the quarter.

Summary

• Bullfrog AI Holdings, Inc. reported its financial results for the third quarter ended September 30, 2024.
• The company did not generate any revenue in the third quarter of 2024, compared to $65,000 in the same period of 2023.
• The net loss attributable to common stockholders was $1.76 million, or $0.22 per share, for the quarter, compared to a net loss of $1.25 million, or $0.21 per share, in the third quarter of 2023.
• Research and development expenses increased to $566,584 for the quarter, up from $380,015 in the same period last year, due to increased personnel costs and expansion of target discovery efforts.
• General and administrative expenses also increased to $1.25 million, up from $983,929 in the third quarter of 2023, primarily due to increased personnel costs and equity compensation.
• The company's cash and cash equivalents stood at $4.24 million as of September 30, 2024, compared to $2.62 million at the end of 2023.
• Bullfrog AI completed a secondary public offering in February 2024, raising approximately $5.7 million in net proceeds, and a registered direct offering in October 2024, raising approximately $2.7 million in net proceeds.
• The company believes its current capital resources are sufficient to fund operations into the fourth quarter of 2025, but will require additional capital to continue executing its strategy.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in securing funding and advancing its research programs, the lack of revenue and increasing losses are concerning. The identified material weaknesses in internal controls also raise concerns. The need for additional capital is a significant risk.

Positives

• The company successfully raised additional capital through secondary and direct offerings, strengthening its financial position.
• Bullfrog AI is actively investing in research and development, expanding its team and initiating preclinical studies.
• The company has secured strategic data and commercialization agreements with the Lieber Institute for Brain Development.
• Bullfrog AI has exclusive worldwide license agreements with Johns Hopkins University and George Washington University for cancer drug development.

Negatives

• The company reported no revenue for the third quarter of 2024.
• The company experienced a net loss of $1.76 million for the quarter.
• The company's operating expenses, including research and development and general and administrative costs, have increased.
• The company has an accumulated deficit of approximately $15.1 million.
• The company has identified material weaknesses in its internal controls over financial reporting.

Risks

• The company has a history of negative cash flows from operations and net losses since inception.
• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no assurance that the company will be able to secure additional funding on acceptable terms.
• The company's success is dependent on the successful development and commercialization of its AI platform and drug assets.
• The company faces risks related to market acceptance, regulatory changes, and competition.
• The company has identified material weaknesses in its internal controls over financial reporting, which could lead to misstatements in its financial statements.

Future Outlook

The company believes its current capital resources are sufficient to fund planned operations into the fourth quarter of 2025, but will require additional capital to continue executing its strategy. They anticipate raising this additional capital through various avenues including sales of equity securities, debt transactions, licensing agreements and collaborative arrangements.

Management Comments

• Management believes the bfLEAP platform is ideally suited for evaluating pre-clinical and clinical trial data.
• Management aims to improve the odds of success in each stage of developing medicine.
• Management intends to secure the rights to other proprietary data sets and repeat this strategy.
• Management is in the process of implementing improvements to its internal controls over financial reporting.

Industry Context

Bullfrog AI is operating in the rapidly evolving fields of artificial intelligence and drug development, where AI/ML is increasingly being used to accelerate and improve the efficiency of drug discovery and clinical trials. The company's focus on precision medicine and rescuing failed drug candidates aligns with industry trends towards more targeted and cost-effective therapeutic development.

Comparison to Industry Standards

• Bullfrog AI's lack of revenue in the current quarter is not uncommon for early-stage biotech companies focused on R&D.
• The increase in R&D expenses is typical for companies in this sector as they advance their programs.
• The company's reliance on external funding is also common for biotech startups, especially those with high R&D costs.
• Companies like Recursion Pharmaceuticals and Exscientia are also using AI for drug discovery, but they have different business models and revenue streams.
• Bullfrog AI's licensing agreements with universities are a common strategy for acquiring promising drug candidates.
• The company's focus on rescuing failed drugs is a niche area, but it could offer significant value if successful.

Stakeholder Impact

• Shareholders may be concerned about the lack of revenue and increasing losses.
• Employees may be impacted by the company's financial performance and potential need for additional funding.
• Customers and partners may be interested in the company's progress in developing its AI platform and drug assets.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to evolve and improve its bfLEAP platform.
• The company plans to leverage its proprietary AI/ML platform for drug development.
• The company intends to secure the rights to other proprietary data sets.
• The company will seek additional capital to continue executing its strategy.
• The company will continue to implement improvements to its internal controls over financial reporting.

Key Dates

Keywords

Artificial Intelligence, Machine Learning, AI/ML, Drug Development, Precision Medicine, Therapeutics, Clinical Trials, bfLEAP, Biopharmaceutical, License Agreements, Data Analysis, Target Discovery, Financial Results, Capital Raise